- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Retrospective, Single centre
- Objective: To determine the efficacy and safety of a combination of two antivirals, with and without a monoclonal antibody, in both the early and later phases of SARS-CoV-2 infection in immunocompromised patients
- Number of participants enrolled: 11
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
External Links
Other information
Funders/Sponsors:
- NextGenerationE UMUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
- POR Campania
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to